Total
0
Shares
MGC Pharma’s (ASX:MXC) first Shipment of CogniCann en route to Australia
  • MGC Pharmaceuticals' (MXC) first bulk shipment of CogniCann is en route to Australia and will arrive in the upcoming days
  • The first shipment will allow the commencement of the phase IIb clinical trials in partnership with the University of Notre Dame in Western Australia
  • The trial will involve 50 patients aged 65 and over, testing the effects of CogniCann on dementia and Alzheimer's patients
  • MGC's share price is currently 1.61 per cent with shares trading for 3.2 cents apiece

MGC Pharmaceuticals' (MXC) first bulk shipment of CogniCann is en route to Australia and will arrive in the upcoming days.

This shipment also includes units for commercial prescriptions under the Special Access Scheme or by authorised prescribers in Australia.

The first shipment will allow the commencement of the phase IIb clinical trials in partnership with the University of Notre Dame in Western Australia.

This study will involve 50 patients aged 65 and over, testing the effects of CogniCann on dementia and Alzheimer's disease patients.

"The first shipment which will enable the commencement of phase IIb clinical trial of CogniCann in Australia is another positive step for us," Co-founder and Managing Director Roby Zomer commented.

"CogniCann has the potential to seriously alleviate the symptoms of patients living with Alzheimer's disease and dementia," he added.

The study will assess the best dose of drug in regard to its effectiveness and safety in targeting symptoms associated with dementia and Alzheimer's.

While it is not a specific disease, dementia is a group of conditions characterised by the impairment of at least two brain functions, most commonly memory loss and judgement.

Some medications and therapies may help manage the symptoms are some causes are reversible.

Alzheimer's is a physical brain disease that causes dementia, resulting in impaired memory, thinking and behaviour.

While treatments such as physical exercise, cognition-enhancing medication and specialists may help no cure currently exists but these treatments may temporarily improve symptoms.

MGC Pharma's share price is up a slight 1.61 per cent with shares trading for 3.2 cents apiece at 11:45 am AEDT.


Subscribe


MXC by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New